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Abstract
Purpose: Treatments for myopia progression are now available, but implementing
these into clinical practice will place a burden on the eye care workforce. This study
estimated the full-time equivalent (FTE) workforce required to implement myopia
control treatments in the UK and Ireland.
Methods: To estimate the number of 6-to 21-year-olds with myopia, two models utilising separate data sources were developed. The examination-based model
used: (1) the number of primary care eye examinations conducted annually and
(2) the proportion of these that are for myopic young people. The prevalence-
based model used epidemiological data on the age-specific prevalence of myopia. The proportion of myopic young people progressing ≥0.25 dioptres (D)/year
or ≥0.50 D/year was obtained from Irish electronic health records and the recommended review schedule from clinical management guidelines.
Results: Using the examination and prevalence models, respectively, the estimated number of young people with myopia was 2,469,943 and 2,235,713. The
extra workforce required to provide comprehensive myopia management for this
target population was estimated at 226–317 FTE at the 0.50 D/year threshold and
433–630 FTE at the 0.25 D/year threshold. Extra visits required for myopia control
treatment represented approximately 2.6% of current primary eye care examinations versus 13.6% of hospital examinations.
Conclusions: Implementing new myopia control treatments in primary care settings over the medium-term is unlikely to overwhelm the eye care workforce completely. Further increases to workforce, upskilling of current workforce and tools to
reduce chair time will help to ensure sustainability of the eye care workforce into
the future.
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ESTIMATING THE WORKFORCE REQUIRED TO TREAT MYOPIA

I NTRO DUC TIO N
Myopia typically develops during childhood and is regularly encountered within eye care clinics. The prevalence of
myopia varies substantially depending on age, geography
and ethnicity and has been estimated to affect between
approximately 7% to 35% of 10-year-old and 13% to 70%
of 15-year-old children.1 The prevalence of myopia is also
increasing in many parts of the world making it a major
public health issue.2
Myopia, particularly high myopia, is associated with
greater risk of irreversible vision loss3 due to associated
eye conditions such as retinal detachment, glaucoma and
myopic macular degeneration.4 A recent Global Burden of
Disease Study estimated that in China (data were sparse
elsewhere), myopic macular degeneration causes more
moderate to severe visual impairment than diabetic retinopathy, age-related macular degeneration (AMD) and
glaucoma, and causes more blindness than diabetic retinopathy, but is similar to AMD.5 Myopia is, therefore, already becoming a leading cause of vision loss in some parts
of the world. Other nations are likely to see similar trends of
increasing myopia-associated vision loss as more myopic,
younger generations age and their risk of myopic macular
degeneration and vision impairment increases;3 the costs
of which are likely to be substantial, both in human and in
economic terms.6
There have been recent advancements in treatments
to reduce the progression of myopia in children.7 These
treatments ultimately aim to lower a child's final myopic refractive error (i.e., in adulthood) and, consequently, reduce
their risk of irreversible vision loss in later life.8 Treatments
shown to have good efficacy in preventing progression of
myopia or axial elongation of the eye (a marker of myopia
progression) include low-dose (0.01%–0.10%) atropine eye
drops9–11 and various optical treatments that impose myopic defocus on the peripheral retina, such as orthokeratology contact lenses12 and certain, specially designed,
soft contact lenses13–15 and spectacles.16 Results from
randomised controlled trials investigating the efficacy
of low-dose atropine in European populations are yet to
emerge,17–19 but orthokeratology, contact lenses and spectacles are currently approved for the treatment of myopia
in Europe.
Over the coming years, the standard of care for optometrists and ophthalmologists is likely to change such
that all children with progressing myopia should be offered myopia control treatment. For instance, in a recent
World Council of Optometry resolution, evidence-based
interventions to slow the progression of myopia were incorporated into the definition of standard of care myopia
management.20 This will require more and longer clinical
visits.21 The relatively high prevalence of myopia, compared to other conditions, means that even a small increase
in required clinic visits to manage myopia could add a large
burden to the eye healthcare system. This study aimed to
estimate the optometry and ophthalmology workforce

Key points
• Recent advances in myopia control treatments
will ultimately prevent vision loss, but implementing these will place an added burden on
the eye care workforce.
• The primary/community eye care sector will be
best-placed to expand capacity to address the
extra visits required to implement myopia control treatments.
• With appropriate management of existing and
emerging eye care workforce supply, the introduction of myopia control services is unlikely
to overwhelm eye care services in the UK and
Ireland.

required to implement treatments for all young people
with progressive myopia in the UK and Ireland and compare it to the estimated current workforce. Importantly, we
aimed to assess the need for myopia control treatment, as
opposed to uptake, to maximise access to myopia control
treatments and minimise future vision loss. The results
of our study will inform evidence-based workforce planning and policy development in the optometry and ophthalmology sectors to ensure that service capacity meets
the evolving population health needs specific to myopia
management.

M E TH O DS
Estimating population with myopia
Two models for estimating the young myopic population
were developed: first, an examination model that was
based on: (1) the current number of primary care eye examinations performed annually in the UK and Ireland and
(2) the proportion of these examinations that are for young
myopic individuals; and second, a prevalence model that
was based on the estimated age-specific prevalence of
myopia. Models were developed for ages 6–21 years as this
group is most likely to have progressive myopia and require myopia control treatment.22 All population estimates
for the Republic of Ireland (ROI),23 Scotland24 and the UK25
overall were obtained from government statistics agencies.

Examination model
Complete data on primary care eye examinations conducted in the UK and Ireland are not available. To estimate
the rate of primary care eye examinations per 100,000
population, we used Scotland National Health Service
(NHS) data. Most eye examinations in Scotland, with
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some exceptions, are free-of-charge for all UK citizens.26
Consequently, data on NHS-funded examinations likely
represent close to 100% of primary care eye examinations
in Scotland. An added benefit is that the recorded number of eye examinations is likely to be closer to the actual
eye care need for that population. In contrast, using data
from another nation, where cost is a barrier to accessing
eye care, would underestimate eye care need. Data on
community-based eye examinations by both optometrists
and ophthalmic medical practitioners were extracted for
the period 01 April 2018 to 31 March 2019,27 to avoid any
impact of the COVID-19 pandemic. The eye examination
rate in Scotland was used to estimate the annual number of
primary care eye examinations in the UK and Ireland. To investigate the feasibility of treating myopia within hospitals,
the number of eye examinations conducted in Scotland
hospital outpatient departments over the same period was
extracted separately.28
The proportion of primary care eye examinations that
are for young myopic people was estimated using electronic health record (EHR) data collected from 30 optometry practices in the ROI (>700,000 patient visits). Applying
this proportion to the number of eye examinations estimates the annual number of examinations conducted for
myopic young people. The Ireland Eye Study (IES)29 found
that approximately 5%–
8% of children with refractive
error had uncorrected or under-corrected refractive error.
Therefore, we conservatively added 5% to the estimated
number of eye examinations to account for unmet need.
It was assumed that myopia control treatments were not
being prescribed in 2018–2019 and that myopic young
people not receiving myopia control treatment are seen
once a year.30

Prevalence model
The number of young people with myopia in the UK and
Ireland was calculated by multiplying, for each year of
age, the estimated prevalence of myopia by the population. Data on the prevalence of myopia were derived
from the IES29 and the Northern Ireland Childhood Errors
of Refraction (NICER) study.31 IES data were used in preference to those from NICER because it was more recent
(2016–2018 vs. 2006–2008) and reported on a mix of ethnicities.29 The IES found the prevalence of myopia in 6–7
(mean 6.7 years, rounded to 7) and 12-to 13-year-olds
(mean 12.8 years, rounded to 13) was 3.3% and 19.9%, respectively. We assumed the incidence of myopia was constant from 6–13 years (incidence = 2.8%/year). Between
ages 13 and 19 years, we used the annual myopia incidence
reported in NICER (0.7%/year).32 There were no myopia
prevalence data for 19–21 years of age. We assumed a four-
fold reduction in myopia incidence at ages 19–21 years, in
line with the change in incidence from age 6–12 years to
13–19 years (incidence = 0.2%/year). Figure 1 shows the estimated age-specific prevalence of myopia.
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F I G U R E 1 The estimated age-specific prevalence of myopia in
Ireland and the UK based on the prevalence model. Estimates of the
prevalence and incidence of myopia are extrapolated from the Ireland
Eye Study and the Northern Ireland Childhood Errors of Refraction
Study.

Progression of myopia
Irish EHR data, which contained data on subjective refraction at each visit, were utilised to calculate the prevalence of progressing myopia. Annual change in spherical
equivalent (dioptres [D]/year) was calculated for right and
left eyes of young people with myopia and the proportion
who were progressing either ≥0.25 or ≥0.50 D/year in either eye was determined. This was calculated for each year
of age for the prevalence model and using all ages combined for the examination model, as the latter did not use
age-specific data. While a 0.25 D change in refraction could
fall within measurement error for subjective refraction, we
chose this cut-off because optometrists and ophthalmologists are likely to measure a 0.25 D change in refractive
error (whether real or not) and make treatment decisions
based on this change alongside other clinical information.

Treatments for myopia progression
Having estimated the population who may benefit from
myopia treatment, we examined separately the required
workforce to provide: (1) low-dose atropine eye drops, (2)
orthokeratology, (3) soft contact lenses (SCL) for myopia
control and (4) spectacles for myopia control, and compared this to the workforce needed to provide refractive
correction alone (no myopia control treatment). The annual
review schedule for each intervention type was extracted
from clinical management guidelines and summarised in
Table 1.34
The mean number of visits for each intervention was
calculated by weighting the recommended number of visits in the first or subsequent year of treatment by the proportion of myopic patients in that year of treatment. For
the examination model, the frequential probability that a
person is in their first year of treatment (11.76%) was calculated by dividing 16 by 16-factorial (16 years of age between 6 and 21, inclusive). For the prevalence model, we
calculated the proportion of all young people with myopia

4
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TA B L E 1

ESTIMATING THE WORKFORCE REQUIRED TO TREAT MYOPIA

Estimated number of visits per person required in a given year for various treatments of myopia, including no treatment
Number of visitsa in 1st
year of treatment

Number of visitsa
after 1st year

Mean number of visitsa
(examination model)

Mean number of visitsa
(prevalence model)

No treatment

1

1

1

1

Atropine

5

2

2.35

2.29

Orthokeratology

6

2

2.47

2.39

Soft contact lenses

4

2

2.23

2.19

Spectacles

3

2

2.12

2.10

Note: Data on number of visits derived from International Myopia Institute Clinical Management Guidelines.
a
All visit numbers are per person per year.

who had incident myopia in the last year (9.63%) and assumed this proportion of patients were in their first year
of treatment. We further assumed that patients remain on
treatment until 21 years of age or until myopia progression
ceases, the latter being based on the estimated proportion
of the myopic population that is progressing.

Short-term impacts of initiating
myopia treatment
These visit estimates are conservative because they overlook that most progressing myopia is not currently being
treated. As more myopia control treatments are prescribed,
a greater number of people will be in their first year of
treatment. Therefore, we also modelled the impact on the
workforce of rolling out myopia treatment in all young people over the following short-term periods: 1 year (assumed
95% are treated first year and 5% are treated the following year); 2 years (50% per year); 3 years (33% per year) and
4 years (25% per year). After the initial short-term spike in
workforce required for myopia control treatment initiation,
the workforce burden will be expected to decrease and
plateau to a constant level, assuming practice guidelines,
treatments and resources remain stable, before gradually
increasing as population and myopia prevalence increases.

Required workforce and current
workforce capacity
Based on a recent optometric workforce survey,33 we assumed that a full-time equivalent (FTE) eye care clinician
(optometrist or ophthalmologist) examines 60 patients per
week and takes 5 weeks of annual leave (minimum entitled
annual leave is 4 weeks in the UK and Ireland). The numbers
of optometrists and ophthalmologists registered in the UK
and Ireland between 2015–2020 were obtained from professional registration councils (CORU, Medical Council of
Ireland, General Optical Council, General Medical Council)
through annual reports or freedom of information requests. We only considered paediatric ophthalmologists
as part of the workforce involved in implementing myopia control treatments and estimated their number from

self-
reported data obtained from the Irish College of
Ophthalmologists and Royal College of Ophthalmologists.
The 2015 UK Optical Workforce Survey34 estimated mean
FTE per registered optometrist to be 0.883 and this was applied to calculate FTE workforce capacity.

Effect of increasing myopia prevalence
The prevalence of myopia is predicted to increase in Europe
at approximately 6%–8% per decade in all ages.2,35 We estimated the impact of this on workforce by modelling the
expected change in myopia prevalence using highly-cited
methods.2 As the estimated prevalence of myopia in the
UK and Ireland was less than 28.3%, a constant increase
in myopia prevalence of 3.8% per year was applied. The
yearly increase in myopia prevalence is expected to be
lower among children of younger ages and a weighting of
0.25 and 0.5 was applied to the yearly change for 5-to 9-
and 10-to 19-year-olds, respectively.

Role of the funding source
No funding was obtained for this study and, therefore,
no funders had input into the study design, analysis or
interpretation.

R ESULTS
Estimating population with myopia
The outcomes of both the examination and prevalence
models for estimating the number of myopic young people
in the UK and Ireland are shown in Figure 2. The estimated
number of myopic young people was similar between the
models at approximately 2.2 to 2.4 million.

Treatments for myopia progression
The estimated mean number of visits for each intervention type is shown in Table 1. Despite the large variation in
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F I G U R E 2 Flowchart showing the process for estimating the number of myopic young people aged 6–21 years using either the examination
model or the prevalence model. For the examination model, eye examinations refer to primary or community care eye examinations only. For the
prevalence model, calculations were done separately for each year of age and data shown is the sum total.

the number of first-year visits between treatment options,
there was little overall difference in the mean number of
visits, reflecting that relatively few patients (~10%) are in
their first year of treatment in a given year. Mean visits were
slightly lower for the prevalence model because this model
accounts for myopia incidence being higher at younger
ages and therefore, relatively few patients are in their first
year of treatment.

Progression of myopia
For all myopic 6-to 21-year-olds combined, mean spherical equivalent was −2.02 D (SD: 1.64) and the proportion with myopia progression of at least 0.25 D/year
and 0.50 D/year in either eye was 48.9% and 24.6%, respectively. Table 2 shows the estimated number of 6-to
21-year-olds with myopia and, of those, the number progressing and the estimated FTE workforce required to
implement each myopia control intervention. Changing
treatment type made little impact on the estimated required FTE workforce. However, compared to 0.50 D/year,
defining myopia progression requiring treatment as a
progression of ≥0.25 D/year approximately doubled the
estimated extra required workforce.

Short-term impacts of initiating
myopia treatment
The data presented up to now do not consider that most
young people are not currently receiving myopia control

treatment. Thus, relatively more people will be in their first
year of treatment in the coming years. The effect of this on
the mean number of visits is shown in Table 3, and the subsequent impact on the required workforce at the ≤−0.50 D/
year threshold is shown in Figure 3. In the most extreme
scenario, initiating myopia control treatment in 95% of
young people in a single year increased the required workforce from around 220–240 FTE to 400–420 FTE for spectacles, and from approximately 280–320 FTE to 990–1030 FTE
for orthokeratology.

Required workforce and current
workforce capacity
On an ongoing basis, treating all progressing myopia at
the 0.50 D/year threshold was estimated to result in approximately an extra 800,000 visits per year (mean of
prevalence and examination models: atropine 822,055;
orthokeratology 893,538; soft contact lenses 750,572;
spectacles 679,089). This equates to a 2.6% (range: 2.2%
to 2.9%) increase in the number of total primary care eye
examinations. Based on Scotland NHS hospital data,28 the
estimated total number of hospital outpatient visits in the
UK and Ireland in 2020 was 5,881,880. Therefore, treating
myopia within the hospital system would approximately
represent a 13.6% (range: 11.5% to 15.2%) increase in outpatient visits.
In the year 2020, there were 2962 ophthalmologists
(2675 [90%] in the UK) and 17,565 optometrists (16,670
[95%] in the UK) registered to practice in the UK and
Ireland. Of ophthalmologists registered with the Irish

6
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ESTIMATING THE WORKFORCE REQUIRED TO TREAT MYOPIA

T A B L E 2 Estimated workforce requirements for the treatment of myopia using either the examination or prevalence model and defining
progression as either ≤−0.25 D/year or ≤−0.50 D/year
Progressing ≤−0.25 D
Examination model

Prevalence model

Estimated number of myopic 6-to 21-year-olds

2,469,943

2,235,713

Estimated number with progressing myopia

1,207,802

1,115,506

Estimated FTE workforce required for no myopia control treatment

876

793

Treatment with atropine

+579

+510

Treatment with orthokeratology

+630

+548

Treatment with soft contact lens

+529

+472

Treatment with spectacles

+479

+433

a

Additional FTE workforce required for:

Progressing ≤−0.50 D
Examination model

Prevalence model

Estimated number of myopic 6-to 21-year-olds

2,469,943

2,235,713

Estimated number with progressing myopia

607,606

582,821

Estimated FTE workforce required for no myopia control treatment

876

793

Treatment with atropine

+291

+266

Treatment with orthokeratology

+317

+286

Treatment with soft contact lens

+266

+246

Treatment with spectacles

+241

+226

a

Additional FTE workforce required for:

a

Number of extra full-time equivalent (FTE) optometric/ophthalmic workforce required to implement treatment, supplementary to the workforce required without
myopia control treatment for myopia progression, that is, annual review for change in spectacle or contact lens prescription.

TA B L E 3

Mean visits per intervention type by proportion of young myopic people in their first year of treatment

Percent in first year of
treatment

Mean visits—Atropine

Mean visits— Orthokeratology

Mean visits—Soft
contact lenses

Mean
visits—Spectacles

25%

2.75

3

2.5

2.25

33%

2.99

3.32

2.66

2.33

50%

3.5

4

3

2.5

95%

4.85

5.8

3.9

2.95

Note: Treatment percent is the percentage of all progressing myopic 6-to 21-year-olds requiring treatment who are in their first year of treatment in a given year. For
example, 95% indicates that, of all myopic 6-to 21-year-olds being treated for myopia progression, 95% are in their first year of treatment. Mean visits are the same for
both the prevalence and examination models.

College of Ophthalmologists and the Royal College of
Ophthalmologists, 21% (33/156) and 8% (156/2146) self-
reported a paediatric subspecialty interest, resulting in an
estimated 60 and 214 paediatric ophthalmologists in the
ROI and the UK, respectively. The ROI likely has a higher proportion because some ophthalmologists (approximately
10%) are community-based and regularly see paediatric
patients. Assuming an average FTE of 0.883 per registration, this equates to a total FTE workforce of 15,752 in the
UK and Ireland, combined. The extra workforce required
to implement myopia treatments represents a relative increase to the existing combined optometry and paediatric
ophthalmology workforce of approximately 1.4% to 2.0%

and 2.8% to 4.0%, depending on the intervention, at the
0.50 and 0.25 D/year thresholds, respectively.

Current workforce trends
Data on the change in the number of FTE optometrists
and ophthalmologists per 100,000 population in the UK
and Ireland are presented, separately, in Figure 4. Between
2015 and 2020, the overall mean relative increase in FTE
optometrists and ophthalmologists was 2.4% and 3.2%,
respectively, but was greater in the UK (2.4%–3.5%), compared with the ROI (0.8%–1.4%).
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F I G U R E 3 Extra full-time equivalent (FTE) workforce (beyond FTE workforce required for no active treatment) required to initiate myopia
treatment in 95%, 50%, 33% and 25% of myopic people aged 6–21 years (progressing at ≤−0.50 D/year threshold) over a period of 1, 2, 3 and 4 years,
respectively. Data are shown for prevalence and examination models separately. Ortho-K , Orthokeratology; SCL, Soft contact lenses.

D ISCUSSIO N

F I G U R E 4 Temporal changes in the estimated full-time equivalent
(FTE) number of optometrists and ophthalmologists in the UK and
Republic of Ireland (ROI), separately. Data are derived from the number
of registrations with the relevant national regulatory council multiplied
by an assumed average 0.883 FTE per registration. In the ROI, mean
annual relative increase in FTE workforce per 100,000 population
between 2015 and 2020 was 1.4% for optometrists and 0.8% for
ophthalmologists and, in the UK, was 3.5% for optometrists and 2.4%
for ophthalmologists.

Effect of increasing myopia prevalence
The prevalence of myopia is expected to increase and additional workforce will be required to manage the higher demand for myopia treatment. The estimated annual mean
increase in the number of myopic 6-to 21-year-olds in the
UK and Ireland is 1.9%. Figure 5 illustrates this increase
and demonstrates that a modest increase in required
FTE is seen: approximately an extra 50 (range 41–52) FTE
in 10 years' time and an extra 100 (range 97 to 136) FTE in
20 years' time.

Treatments for myopia progression will allow clinicians to
alter the course of myopia and, ultimately, prevent vision
loss.8 However, implementing such treatments could place
a substantial burden on the eye care workforce. This situation is not unprecedented; for example, the emergence
of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration placed a large
burden on tertiary eye care services.36 We estimated that
the extra workforce capacity required to treat progressing
myopia is relatively small, approximately 250–550 FTE staff
in the UK and Ireland, if the service is rolled out over 3 to
4 years. This represents an increase of around 1%–3% of the
entire optometry and ophthalmology workforce. However,
initial requirements will be higher as a larger proportion of
myopic young people enter their first year of treatment.
Implementing treatments over a 3-year period appeared
to provide a good balance between managing workforce
capacity and enabling timely access to treatment.
Intervention type only had a substantial impact on
workforce requirement when initiating myopia treatments
over the shorter-term. For example, if 95% of young progressing individuals with myopia were to start treatment
next year, the required workforce tripled for treatment with
orthokeratology, compared to the longer-term estimates
in Table 2, and was more than twice that required to treat
children with myopia control spectacles alone. However,
the differences between treatments became minimal in
the longer term. It is unlikely and unfeasible that myopia
control treatments could be rolled out in a 1-year period
and there will probably be a natural delay in the uptake of
treatments. While we estimated that implementing myopia
control treatments with spectacles required the smallest

8
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ESTIMATING THE WORKFORCE REQUIRED TO TREAT MYOPIA

F I G U R E 5 Estimated increases in extra full-time equivalent (FTE) workforce (beyond that required for no active treatment) for each treatment
type over a 20-year period. Increases in FTE are related to a predicted increase in the prevalence of myopia in this age group of approximately 1.9%.
Ortho-K , Orthokeratology; SCL, Soft contact lenses.

workforce increase, training and equipment requirements
differ between interventions. We have not factored these
expenses into this study as decisions on provision of an intervention are likely to be driven by financial, preference
and efficacy considerations at the clinic-and patient-level.
The progression threshold for initiating myopia treatment was an important factor. Compared to a threshold
of 0.50 D/year, treating myopia progression at 0.25 D/year
approximately doubled the required extra FTE workforce.
There is currently no consensus on a threshold at which to
initiate myopia treatment,21 and future recommendations
on treatment thresholds may need to consider the impact
of workforce capacity. As clinicians adapt to providing
myopia control treatments, greater capacity to treat progressing myopia may become available or further evidence
may arise to guide clinical decision-making through, for
example, updates on clinical management guideline recommendations and review schedules or additional tools to
reduce the length of visits.
A full assessment of current workforce capacity in the
optometry and ophthalmology sectors was beyond the
scope of this study. We estimated the current FTE workforce based on professional registrations, but this does not
provide information on whether ‘spare’ FTE capacity exists
within the current eye care workforce, or whether additional optometrists and ophthalmologists need to be recruited or trained. It is also possible that the role or scope of
practice of other existing staff and professionals within the
eye care sector will expand to take on some of the burden
of treating myopia; thus reducing demand on the optometry and ophthalmology sectors.
It is unlikely that myopia control treatments could occur
entirely within hospitals (requires 14% increase in capacity),
particularly given that visits would almost entirely occur
within paediatric clinics, which are a small proportion of
all hospital eye care services. Primary care optometrists
and community-
based ophthalmologists are therefore
best placed to provide myopia treatments; however, other

barriers, such as lack of appropriate training,37 will need to
be addressed. Differences in prescribing rights for optometrists also exist; for instance, UK optometrists can prescribe
atropine eye drops, but ROI optometrists cannot. Hence,
uptake of low-dose atropine treatment in the ROI would
be limited by community-based ophthalmology capacity.
Reassuringly, there has been a 2%–3% annual increase in
the number of FTE optometrists and ophthalmologists
per 100,000 population in the UK and Ireland over the last
5 years. While this approximately matches the FTE workforce required for myopia treatments, other demands on
the eye care workforce that come from ageing populations
and provision of other treatments cannot be neglected.
Therefore, it is likely that strategies to reduce workforce requirement, such as through more efficient provision of services, will be needed to meet ongoing demand for myopia
treatments. The cost of treatment to the patient is another
factor that will affect uptake of myopia control treatments
and, consequently, workforce demand. Our estimates represent a scenario where cost is not a barrier to uptake, but,
if treatments are not subsidised and costs remain steady,
uptake and workforce demand is likely to be lower.
The workforce estimates in the present study are likely
to be conservative and there are additional factors we
did not incorporate. The models assumed that all people
whose myopia naturally ceases to progress will stop treatment. However, clinicians are likely to attribute any natural reduction in myopia progression to a treatment effect
and thus continue treatment, resulting in more prolonged
treatment durations. We limited the population to ages
6–21 years; some adults aged 22 years or older may also require treatment, but myopia progression at this age is generally low.38 Additional factors may partially balance these
conservative assumptions. We assumed myopia control
treatments were not being utilised in the years 2019–2020,
whereas it is likely that soft contact lenses and orthokeratology lenses were being prescribed, albeit for a minority
of children. Thus, the extra FTE workforce required could

LINGHAM et al.

be lower than that estimated. In practice, clinicians measuring a 0.25 D change in refraction without accompanying visual acuity changes may not view this as evidence
of myopia progression (due to measurement error) and
hence not initiate myopia control treatment. Relative to
the 0.50 D/year threshold, the increase in FTE workforce
associated with treating myopia at the 0.25 D/year threshold may therefore actually be lower than estimated in this
study, but will be higher than estimated at the 0.50 D/year
threshold. Adverse events associated with myopia control
treament10,15,39 are likely to require extra visits beyond that
estimated in this study. We additionally did not consider
differences in ‘chair time’ for the different myopia interventions. Currently, the International Myopia Institute (IMI)
clinical guidelines recommend that all assessments be repeated at every visit, but, in practice, visit lengths are likely
to be quicker for interim than baseline or annual reviews.
Without evidence to guide our assessment, we opted to
focus on the number of visits for our calculations, rather
than visit length. Estimated required workforce will additionally vary depending on national myopia prevalence,
and may be much lower or higher in countries with a low
or high prevalence of myopia, respectively. Finally, we did
not investigate the costs associated with myopia control
treatments, both in terms of the treatments themselves, as
well as in terms of additional training, resources or equipment. These costs may present an additional barrier to patients accessing, or practitioners providing, myopia control
treatments.
There are some limitations to this study. First, we assumed it was valid to combine workforces from the ROI
and the UK. Differences in their respective healthcare
systems exist, such as relatively more community-based
ophthalmologists in the ROI, but these differences are not
major. There are substantial cultural and demographic similarities between the UK and ROI as well as similarities in
the healthcare system plus cross-over and movement of
workforce between the UK and the ROI. A key assumption
for both the examination and prevalence models is that
data from each of the ROI, Northern Ireland and Scotland
are representative of the wider UK and Irish population. For
example, we assumed that eye care need in Scotland, as
estimated from eye examination data, is consistent with
that in the UK and Ireland. Using Scottish data may represent a ‘best-case’ scenario where cost is not a barrier to
accessing eye care; however, alternative barriers to health
care, such as lack of access or trust in healthcare systems
or ethnic differences in healthcare utilisation could all
contribute to underestimation of true eye care need. To
conservatively account for under-utilisation, we added 5%
to all eye examinations. Population ethnicity differences
may also impact estimated myopia prevalence.1 The most
recent census data on population ethnicity in the UK are
from 2011, in which 85%, 96%, 96% and 98% identified as
being of white ethnicity in England, Wales, Scotland and
Northern Ireland, respectively, and 94% of the ROI population reported being of white ethnicity in the same year.
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The proportion of white children in the IES was slightly
lower than the entire 2011 population, likely because it
was conducted more recently and in Dublin, and is approximately comparable with the total 2011 UK population
(89% vs. 87%).29,40 White children tend to have less myopia compared to non-white children,29,41 and thus, the true
myopia prevalence may be underestimated in this study.
The IES was also conducted in urban areas, where myopia
prevalence is generally higher,42 and this may have led to
an overestimation of the prevalence of myopia. Irish EHR
data were largely from non-cycloplegic examinations, and
the prevalence and progression of myopia in this data set
may therefore have been overestimated. Whether Irish
EHR data are representative of UK EHR data is unclear. The
only approximately comparable UK EHR data set was an
abstract43 that reported mean spherical equivalent in 5-to
15-year-olds in 2002–2004 to be −1.58 D; this is somewhat
comparable to the −2.02 D value noted in this study, given
the UK data are from nearly two decades earlier. It is generally unclear whether the combined effect of errors in these
assumptions would result in an over-or underestimation of
myopia prevalence. More comprehensive data are unlikely
to become available in the near future and conducting a
large study to address gaps in the data used to guide our
assumptions is unlikely to be cost-effective. Additionally,
the use of EHR data reflects real-world clinician measurements upon which treatment decisions are based. The estimates obtained independently from the examination and
prevalence models were relatively similar, differing by only
approximately 10%. Given these models used different
data sources and assumptions, this is somewhat reassuring
that any errors in the assumptions did not have a particularly large impact.
In summary, an increase in the eye care workforce of approximately 250–300 and 450–600 FTE is required for the
ongoing provision of myopia treatment at thresholds of
0.50 D and 0.25 D/year, respectively, and this will be higher
in the short-term. This represents a relatively small increase
in the current FTE workforce. However, to avoid overwhelming eye care service capacity, it will be necessary to
maintain or increase growth of the eye care workforce, provide additional training for the current workforce, manage
the speed at which myopia control treatments are implemented into practice and generate further evidence and
tools to optimise clinical review schedules and reduce visit
length. Arresting current upward trends in the prevalence
of myopia will also be crucial in easing pressure on service
capacity. Appropriate workforce training and planning will
ensure young people can access treatments for myopia
progression, ultimately preventing vision loss in later life.
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